Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Emergency Shortages Data Collection System, 36824-36825 [2015-15641]
Download as PDF
36824
Federal Register / Vol. 80, No. 123 / Friday, June 26, 2015 / Notices
Dated: June 23, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–15711 Filed 6–25–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0197]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Emergency
Shortages Data Collection System
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by July 27,
2015.
SUMMARY:
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0491. Also
include the FDA docket number found
in brackets in the heading of this
document.
ADDRESSES:
FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 8455
Colesville Rd., COLE–14526, Silver
Spring, MD 20993–0002, PRAStaff@
fda.hhs.gov.
FOR FURTHER INFORMATION CONTACT:
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
Emergency Shortages Data Collection
System—(OMB Control Number 0910–
0491)—Extension
Under section 903(d)(2) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C.
393(d)(2)), the Commissioner of Food
and Drugs is authorized to implement
general powers (including conducting
research) to carry out effectively the
mission of FDA. Subsequent to the
events of September 11, 2001, and as
part of broader counterterrorism and
emergency preparedness activities,
FDA’s Center for Devices and
Radiological Health (CDRH) began
developing operational plans and
interventions that would enable CDRH
to anticipate and respond to medical
device shortages that might arise in the
context of Federally declared disasters/
emergencies or regulatory actions. In
particular, CDRH identified the need to
acquire and maintain detailed data on
domestic inventory, manufacturing
capabilities, distribution plans, and raw
material constraints for medical devices
that would be in high demand, and/or
would be vulnerable to shortages in
specific disaster/emergency situations
or following specific regulatory actions.
Such data could support prospective
risk assessment, help inform risk
mitigation strategies, and support realtime decision-making by the
Department of Health and Human
Services during actual emergencies or
emergency preparedness exercises.
FDA developed ‘‘The Emergency
Medical Device Shortages Program
Survey’’ in 2002 to support the
acquisition of such data from medical
device manufacturers. In 2004, CDRH
changed the process for the data
collection, and the electronic database
in which the data were stored was
formally renamed the ‘‘Emergency
Shortages Data Collection System’’
(ESDCS). Recognizing that some of the
data collected may be commercially
confidential, access to the ESDCS is
restricted to members of the CDRH
Emergency Shortage Team (EST) and
senior management with a need-toknow. At this time, the need-to-know
senior management personnel are
limited to two senior managers. Further,
the data are used by this defined group
only for decision making and planning
in the context of a Federally declared
disaster/emergency, an official
emergency preparedness exercise, or a
potential public health risk posed by
non-disaster-related device shortage.
The data procurement process
consists of an initial scripted telephone
call to a regulatory officer at a registered
manufacturer of one or more key
medical devices tracked in the ESDCS.
In this initial call, the EST member
describes the intent and goals of the
data collection effort and makes the
specific data request. After the initial
call, one or more additional follow-up
calls and/or electronic mail
correspondence may be required to
verify/validate data sent from the
manufacturer, confirm receipt, and/or
request additional detail. Although the
regulatory officer is the agent who the
EST member initially contacts,
regulatory officers may designate an
alternate representative within their
organization to correspond subsequently
with the CDRH EST member who is
collecting or verifying/validating the
data.
Because of the dynamic nature of the
medical device industry, particularly
with respect to specific product lines,
manufacturing capabilities, and raw
material/subcomponent sourcing, it is
necessary to update the data in the
ESDCS at regular intervals. The EST
makes such updates on a regular basis,
but makes efforts to limit the frequency
of outreach to a specific manufacturer to
no more than every 4 months.
The ESDCS will only include those
medical devices for which there will
likely be high demand during a specific
emergency/disaster, or for which there
are sufficiently small numbers of
manufacturers such that disruption of
manufacture or loss of one or more of
these manufacturers would create a
shortage.
In the Federal Register of March 18,
2015 (80 FR 14138), FDA published a
60-day notice requesting public
comment on the proposed collection of
information. No comments were
received.
FDA estimates the burden of this
collection of information as follows:
tkelley on DSK3SPTVN1PROD with NOTICES
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Activity/FD&C act section
Number of
respondents
Number of
responses per
respondent
Total annual
responses
Average burden
per response
Total hours
Emergency Shortages Data Collection System (903(d)(2)) ........
125
3
375
0.5 (30 minutes)
188
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
VerDate Sep<11>2014
18:15 Jun 25, 2015
Jkt 235001
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
E:\FR\FM\26JNN1.SGM
26JNN1
Federal Register / Vol. 80, No. 123 / Friday, June 26, 2015 / Notices
FDA based the burden estimates in
Table 1 of this document on past
experience with direct contact with the
medical device manufacturers and
anticipated changes in the medical
device manufacturing patterns for the
specific devices being monitored. FDA
estimates that approximately 125
manufacturers would be contacted by
telephone and/or electronic mail 3 times
per year either to obtain primary data or
to verify/validate data. Because the
requested data represent data elements
that are monitored or tracked by
manufacturers as part of routine
inventory management activities, it is
anticipated that for most manufacturers,
the estimated time required of
manufacturers to complete the data
request will not exceed 30 minutes per
request cycle.
Dated: June 22, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–15641 Filed 6–25–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Advisory Committee on Heritable
Disorders in Newborns and Children
Request for Nominations
Health Resources and Services
Administration, HHS.
ACTION: Notice of request for
nominations.
AGENCY:
The Health Resources and
Services Administration (HRSA) is
seeking nominations of qualified
candidates to be considered for
appointment as members of the
Advisory Committee on Heritable
Disorders in Newborns and Children
(Committee). The Committee provides
advice, recommendations, and technical
information about aspects of heritable
disorders and newborn and childhood
screening to the Secretary of Health and
Human Services. HRSA is seeking
nominations of qualified candidates to
fill three positions on the Committee.
tkelley on DSK3SPTVN1PROD with NOTICES
SUMMARY:
Authority: Section 1111 of the Public
Health Service (PHS) Act, Title XI,
§ 1111(g)(1) (42 U.S.C. 300b–10(g)(1)), as
amended by the Newborn Screening Saves
Lives Reauthorization Act of 2014. The
Committee is governed by the Federal
Advisory Committee Act (FACA), as
amended (5 U.S.C. App.), and 41 CFR part
102–3 and 41 CFR part 102–3, which set
forth standards for the formation and use of
advisory committees.
VerDate Sep<11>2014
18:15 Jun 25, 2015
Jkt 235001
Written nominations for
membership on the Committee must be
received on or before July 27, 2015.
ADDRESSES: Nomination packages must
be submitted electronically as email
attachments to Ms. Lisa M. Vasquez,
Genetic Services Branch, Maternal and
Child Health Bureau, Health Resources
and Services Administration, lvasquez@
hrsa.gov.
FOR FURTHER INFORMATION CONTACT: Ms.
Lisa Vasquez, Genetic Services Branch,
Maternal and Child Health Bureau,
HRSA, at lvasquez@hrsa.gov or (301)
443–4948. A copy of the Committee
Charter and list of the current
membership can be obtained by
accessing the Advisory Committee Web
site at https://www.hrsa.gov/
advisorycommittees/mchbadvisory/
heritabledisorders.
SUPPLEMENTARY INFORMATION: The
Committee is chartered under section
1111 of the Public Health Service (PHS)
Act, 42 U.S.C. 300b–10, as amended by
the Newborn Screening Saves Lives
Reauthorization Act of 2015 (Act). The
Committee was established in 2003 to
advise the Secretary of the U.S.
Department of Health and Human
Services regarding newborn screening
tests, technologies, policies, guidelines,
and programs for effectively reducing
morbidity and mortality in newborns
and children having or at risk for
heritable disorders. In addition, the
Committee provides advice and
recommendations to the Secretary
concerning the grants and projects
authorized under section 1109 of the
PHS Act and technical information to
develop policies and priorities for
grants, including those that will
enhance the ability of the state and local
health agencies to provide for newborn
and child screening, counseling and
health care services for newborns, and
children having or at risk for heritable
disorders.
The Committee is governed by the
provisions of Public Law 92–463, as
amended (5 U.S.C. App. 2), and 41 CFR
part 102–3, which set forth standards for
the formation and use of advisory
committees. The Committee reviews
and reports regularly on newborn and
childhood screening practices for
heritable disorders, recommends
improvements in the national newborn
and childhood heritable screening
programs, and recommends conditions
for inclusion in the Recommended
Uniform Screening Panel (RUSP). The
Committee’s recommendations
regarding additional conditions/
inherited disorders for screening that
have been adopted by the Secretary are
included in the RUSP and constitute
DATES:
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
36825
part of the comprehensive guidelines
supported by the Health Resources and
Services Administration. Pursuant to
section 2713 of the Public Health
Service Act, codified at 42 U.S.C.
300gg–13, non-grandfathered health
plans and group and individual health
insurance issuers are required to cover
screenings included in the HRSAsupported comprehensive guidelines
without charging a co-payment, coinsurance, or deductible for plan years
(i.e., in the individual market, policy
years) beginning on or after the date that
is 1 year from the Secretary’s adoption
of the condition for screening.
Nominations: HRSA is requesting
nominations to fill three (3) positions
for voting members to serve on the
Committee. Nominations of potential
candidates for consideration are being
sought for individuals who are medical,
technical, public health, or scientific
professionals with special expertise in
the field of heritable disorders or in
providing screening, counseling, testing,
or specialty services for newborns and
children at risk for heritable disorders;
who have expertise in ethics (i.e.,
bioethics) and infectious diseases and
who have worked and published
material in the area of newborn
screening; members of the public having
special expertise about or concern with
heritable disorders; or members from
such federal agencies, public health
constituencies, and medical
professional societies as determined to
be necessary by the Secretary. Interested
applicants may self-nominate or be
nominated by another individual and/or
organization.
Individuals selected for appointment
to the Committee will be invited to
serve for up to 4 years. Members who
are not federal officers or permanent
federal employees are appointed as
special government employees and
receive a stipend and reimbursement for
per diem and any travel expenses
incurred for attending Committee
meetings and/or conducting other
business on behalf of the Committee, as
authorized by section 5 U.S.C. 5703 for
persons employed intermittently in
government service. Members who are
officers or employees of the United
States Government shall not receive
additional compensation for service on
the Committee, but receive per diem
and travel expenses incurred for
attending Committee meetings and/or
conducting other business on behalf of
the Committee. Nominees will be
invited to serve during calendar year
2016.
The following information must be
included in the package of materials
submitted for each individual being
E:\FR\FM\26JNN1.SGM
26JNN1
Agencies
[Federal Register Volume 80, Number 123 (Friday, June 26, 2015)]
[Notices]
[Pages 36824-36825]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-15641]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-N-0197]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Emergency Shortages
Data Collection System
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by July
27, 2015.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0491.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver
Spring, MD 20993-0002, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Emergency Shortages Data Collection System--(OMB Control Number 0910-
0491)--Extension
Under section 903(d)(2) of the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 393(d)(2)), the Commissioner of Food and Drugs is authorized
to implement general powers (including conducting research) to carry
out effectively the mission of FDA. Subsequent to the events of
September 11, 2001, and as part of broader counterterrorism and
emergency preparedness activities, FDA's Center for Devices and
Radiological Health (CDRH) began developing operational plans and
interventions that would enable CDRH to anticipate and respond to
medical device shortages that might arise in the context of Federally
declared disasters/emergencies or regulatory actions. In particular,
CDRH identified the need to acquire and maintain detailed data on
domestic inventory, manufacturing capabilities, distribution plans, and
raw material constraints for medical devices that would be in high
demand, and/or would be vulnerable to shortages in specific disaster/
emergency situations or following specific regulatory actions. Such
data could support prospective risk assessment, help inform risk
mitigation strategies, and support real-time decision-making by the
Department of Health and Human Services during actual emergencies or
emergency preparedness exercises.
FDA developed ``The Emergency Medical Device Shortages Program
Survey'' in 2002 to support the acquisition of such data from medical
device manufacturers. In 2004, CDRH changed the process for the data
collection, and the electronic database in which the data were stored
was formally renamed the ``Emergency Shortages Data Collection System''
(ESDCS). Recognizing that some of the data collected may be
commercially confidential, access to the ESDCS is restricted to members
of the CDRH Emergency Shortage Team (EST) and senior management with a
need-to-know. At this time, the need-to-know senior management
personnel are limited to two senior managers. Further, the data are
used by this defined group only for decision making and planning in the
context of a Federally declared disaster/emergency, an official
emergency preparedness exercise, or a potential public health risk
posed by non-disaster-related device shortage.
The data procurement process consists of an initial scripted
telephone call to a regulatory officer at a registered manufacturer of
one or more key medical devices tracked in the ESDCS. In this initial
call, the EST member describes the intent and goals of the data
collection effort and makes the specific data request. After the
initial call, one or more additional follow-up calls and/or electronic
mail correspondence may be required to verify/validate data sent from
the manufacturer, confirm receipt, and/or request additional detail.
Although the regulatory officer is the agent who the EST member
initially contacts, regulatory officers may designate an alternate
representative within their organization to correspond subsequently
with the CDRH EST member who is collecting or verifying/validating the
data.
Because of the dynamic nature of the medical device industry,
particularly with respect to specific product lines, manufacturing
capabilities, and raw material/subcomponent sourcing, it is necessary
to update the data in the ESDCS at regular intervals. The EST makes
such updates on a regular basis, but makes efforts to limit the
frequency of outreach to a specific manufacturer to no more than every
4 months.
The ESDCS will only include those medical devices for which there
will likely be high demand during a specific emergency/disaster, or for
which there are sufficiently small numbers of manufacturers such that
disruption of manufacture or loss of one or more of these manufacturers
would create a shortage.
In the Federal Register of March 18, 2015 (80 FR 14138), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. No comments were received.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
Activity/FD&C act section Number of responses per Total annual Average burden per Total hours
respondents respondent responses response
--------------------------------------------------------------------------------------------------------------------------------------------------------
Emergency Shortages Data Collection System 125 3 375 0.5 (30 minutes) 188
(903(d)(2))...................................
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
[[Page 36825]]
FDA based the burden estimates in Table 1 of this document on past
experience with direct contact with the medical device manufacturers
and anticipated changes in the medical device manufacturing patterns
for the specific devices being monitored. FDA estimates that
approximately 125 manufacturers would be contacted by telephone and/or
electronic mail 3 times per year either to obtain primary data or to
verify/validate data. Because the requested data represent data
elements that are monitored or tracked by manufacturers as part of
routine inventory management activities, it is anticipated that for
most manufacturers, the estimated time required of manufacturers to
complete the data request will not exceed 30 minutes per request cycle.
Dated: June 22, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-15641 Filed 6-25-15; 8:45 am]
BILLING CODE 4164-01-P